<SEC-DOCUMENT>0001683168-17-002347.txt : 20170912
<SEC-HEADER>0001683168-17-002347.hdr.sgml : 20170912
<ACCEPTANCE-DATETIME>20170912083009
ACCESSION NUMBER:		0001683168-17-002347
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170908
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170912
DATE AS OF CHANGE:		20170912

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37487
		FILM NUMBER:		171080094

	BUSINESS ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of
the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event reported):
September 8, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AETHLON MEDICAL, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Nevada</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">of incorporation)</P></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">001-37487</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Commission File Number)</P></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">13-3632859</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Identification Number)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">9635 Granite Ridge Drive, Suite 100</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">San Diego, California</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">92123</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Zip Code)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (858) 459-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former name or former address, if changed since
last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">This Form 8-K and other reports filed by Registrant from time to
time with the Securities and Exchange Commission (collectively, the &quot;Filings&quot;) contain or may contain forward-looking
statements and information that are based upon beliefs of, and information currently available to, Registrant's management as well
as estimates and assumptions made by Registrant's management. When used in the Filings the words &quot;anticipate,&rdquo; &quot;believe,&quot;
&quot;estimate,&quot; &quot;expect,&quot; &quot;future,&quot; &quot;intend,&quot; &quot;plan&quot; or the negative of these terms
and similar expressions as they relate to Registrant or Registrant's management identify forward-looking statements. Such statements
reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other
factors relating to Registrant's industry, Registrant's operations and results of operations and any businesses that may be acquired
by Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect,
actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Although Registrant believes that the expectations reflected in
the forward-looking statements are reasonable, Registrant cannot guarantee future results, levels of activity, performance or achievements.
Except as required by applicable law, including the securities laws of the United States, Registrant does not intend to update
any of the forward-looking statements to conform these statements to actual results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ITEM 8.01 Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On August 11, 2017, we submitted an Expedited Access Pathway (EAP)
program submission to The Center for Devices and Radiological Health (CDRH) of the United States Food and Drug Administration (FDA).
<FONT STYLE="color: #262626; background-color: white">A criterion for&nbsp;EAP program&nbsp;eligibility includes medical devices
that represent breakthrough technologies with the potential to&nbsp;address life threatening disease conditions for which no approved
or cleared treatment alternatives&nbsp;exist. In our EAP submission, we proposed the &ldquo;indication for use&rdquo; for our lead
therapeutic candidate to be, </FONT>&quot;The Hemopurifier is a single-use device indicated for the treatment of life-threatening
highly glycosylated viruses that are not addressed with an approved treatment.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On September 8, 2017, we received a letter from the FDA informing
us that our combination product and proposed &ldquo;indication for use&rdquo; meets the EAP criteria and that our Hemopurifier
has been granted EAP designation. Under the EAP program, we will work collaboratively with FDA to design a data development plan
and regulatory pathway intended to achieve FDA-approval of the device, and through this process, we believe the regulatory advancement
of our device with the FDA will be accelerated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="color: #262626">The FDA established
the&nbsp;EAP program&nbsp;for&nbsp;medical devices that demonstrate the&nbsp;potential to address unmet medical needs for life
threatening or irreversibly debilitating diseases or conditions that are subject to premarket approval applications (PMA), premarket
notification (510[k]) or requests for De Novo designation. &nbsp;</FONT><FONT STYLE="color: #333333">Under EAP, the FDA works with
device sponsors to try to reduce the time and cost from development to marketing decision without changing the FDA's PMA approval
standard of reasonable assurance of safety and effectiveness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #262626">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The Aethlon Hemopurifier is a medical
device&nbsp;designed for the single-use removal of viral pathogens from circulatory system of infected individuals. &nbsp;Based
on clinical and preclinical study outcomes, the Hemopurifier is a candidate to treat a&nbsp;broad-spectrum of&nbsp;life threatening
viruses <FONT STYLE="color: #262626">for which no approved or cleared treatment alternatives&nbsp;exist.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #262626">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #262626"><B>ITEM 9.01 Financial
Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #262626"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #262626"><B>(d) Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #262626">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #262626">99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="aethlon_8k-ex9901.htm">Letter from the FDA to the Registrant, dated September 8, 2017</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 54%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AETHLON MEDICAL, INC.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: white 3pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: white 3pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: white 3pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: white 3pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;<U>/s/ James B. Frakes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James B. Frakes</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: September 12, 2017</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aethlon_8k-ex9901.htm
<DESCRIPTION>LETTER FROM THE FDA
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 27%">&nbsp;</TD>
    <TD STYLE="width: 57%; border-bottom: Black 1pt solid"><B>DEPARTMENT OF HEALTH &amp; HUMAN SERVICES</B></TD>
    <TD STYLE="width: 16%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 7pt">Public Health Service</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;<IMG SRC="ex9901_image.jpg" ALT=""></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 7pt">Food and Drug Administration<BR>
    10903 New Hampshire Avenue<BR>
    Document Control Center - WO66-G609 <BR>
    Silver Spring, MD 20993-0002</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">September 8, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#8453; Ronald S. Warren</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Senior Director Regulatory Affairs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Experien Group, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">224 Airport Parkway, Suite 250</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">San Jose, CA 95110</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font-size: 10pt">Q171414</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Trade/Device Name: Aethlon Hemopurifier</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Received: August 14, 2017</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Dear Ronald S. Warren:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Center for Devices and Radiological Health (CDRH) of the Food
and Drug Administration (FDA) has received the above submission dated August 11, 2017, including your request for Expedited Access
Pathway (EAP) designation. The proposed indications for use includes &quot;The Hemopurifier is a single-use device indicated for
the treatment of life-threatening highly glycosylated viruses that are not addressed with an approved treatment.&quot; We are pleased
to inform you that your combination product and proposed indication for use meets the criteria and has been granted EAP designation.
Please refer to the guidance entitled, &quot;Expedited Access for Premarket Approval and De Novo Medical Devices Intended for Unmet
Medical Need for Life Threatening or Irreversibly Debilitating Diseases or Conditions&quot; available at <FONT STYLE="color: blue">http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocu
<U>ments/UCM393978.pdf</U></FONT> and section 3051 of the 21st Century Cures Act for additional information. As noted in the EAP
Guidance, &quot;Combination products may raise unique scientific and regulatory challenges.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We recommend you use the Pre-Submission review process, as described
in the Pre-Submission guidance, to request any additional feedback from FDA on any issues related to this submission. When submitting
any new requests, please reference Q171414. Any new submission should include two copies (one hardcopy and a valid ecopy), the
FDA reference number for this submission, and should be submitted to the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 140pt">U.S. Food and Drug Administration</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 140pt">Center for Devices and Radiological Health</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 140pt">IDE Document Control Center - WO66-G609</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 140pt">10903 New Hampshire Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 140pt">Silver Spring, MD 20993-0002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 140pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">You are reminded that it is imperative that the information used
to support a premarket submission meets the requirements of valid scientific evidence (21 CFR 860.7). You are further advised that
the granting of EAP designation and priority review does not guarantee that the application will ultimately be approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If you have any questions, please contact Elizabeth Gonzalez, Ph.D.
at (301) 796-6826 or <FONT STYLE="color: blue">Elizabeth.Gonzalez@fda.hhs.gov<U>.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-size: 10pt">Sincerely,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left"><U>/s/ Joyce M. Whang - S</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">for</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Benjamin R. Fisher, Ph.D.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Division of Reproductive, Gastro-Renal,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">and Urological Devices</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Office of Device Evaluation</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Center for Devices and Radiological Health</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex9901_image.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex9901_image.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !G %L# 2(  A$! Q$!_\0
M'  !  (# 0$!              0&!0<( 0,"_\0 -!   @$# P0! @4# @<
M     0(#! 41  82!Q,A,2(400@5,E%Q(T)A%I$7)%-R@8*A_\0 % $!
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MY#'EB-!ZSR.2?D'4-IN5%>+=!7VNJAK**=>44\+AT<>O!'^<C_QJ7K7/X?\
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M3BX88>-@?#*#X/VUS!T=O,W2/K=>=F[DNE+369RRF26=DIXB5$L3KR8JG)2
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=IIH&FFF@::::!IIIH&FFF@::::!IIIH&FFF@_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
